Natixis Invests $1.74 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Natixis acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 92,250 shares of the company's stock, valued at approximately $1,738,000. Natixis owned 0.20% of Pacira BioSciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC grew its position in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after acquiring an additional 1,208 shares during the period. Caitlin John LLC lifted its stake in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after buying an additional 918 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Trading Down 1.7 %

PCRX opened at $25.45 on Wednesday. The business has a fifty day moving average price of $24.51 and a 200 day moving average price of $21.28. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -12.54 and a beta of 0.71.

Analyst Ratings Changes

Several brokerages have weighed in on PCRX. HC Wainwright increased their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC restated a "buy" rating and set a $32.00 price target on shares of Pacira BioSciences in a research report on Tuesday, April 8th. Finally, Barclays boosted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $26.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.